4-chloro-N-(4-(7-methoxy-1,5-naphthyridin-4-ylthio)phenyl)phthalazin-1-amine | 1071537-72-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-chloro-N-(4-(7-methoxy-1,5-naphthyridin-4-ylthio)phenyl)phthalazin-1-amine
• 英文别名: 4-chloro-N-(4-((7-methoxy-1,5-naphthyridin-4-yl)sulfanyl)phenyl)-1-phthalazinamine；4-chloro-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)sulfanyl]phenyl]phthalazin-1-amine
• CAS: 1071537-72-8
• 化学式: C₂₃H₁₆ClN₅OS
• 分子量: 445.932
• InChiKey: BNWIZKDBRGWJGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  98.1
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3,3-二甲基-1-丁炔 、 4-chloro-N-(4-(7-methoxy-1,5-naphthyridin-4-ylthio)phenyl)phthalazin-1-amine 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 三乙胺 作用下， 以 乙腈 为溶剂， 反应 16.0h， 生成 4-(3,3-dimethylbut-1-ynyl)-N-(4-(7-methoxy-1,5-naphthyridin-4-yloxy)phenyl)phthalazin-1-amine
  参考文献：
  名称：

  WO2008/124083

  摘要：

  公开号：

文献信息

• Aurora Kinase Modulators and Method of Use
  申请人：Amgen Inc.

  公开号：US20140336182A1

  公开（公告）日：2014-11-13

  The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1-8、D'、L1、L2、R1、R6-8和n在此处定义，并且具有调节各种蛋白激酶受体酶并因此影响与这些激酶活动相关的各种疾病状态和病况的能力的合成中间体。例如，这些化合物能够调节枢纽激酶，从而影响细胞周期和细胞增殖过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。
• Aurora kinase modulators and method of use
  申请人：Cee Victor

  公开号：US20090069297A1

  公开（公告）日：2009-03-12

  The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n在此定义，并且合成中间体，它们能够调节各种蛋白激酶受体酶，并因此影响与这些激酶活动相关的各种疾病状态和情况。例如，这些化合物能够调节极化激酶，从而影响细胞周期和细胞增殖过程，以治疗癌症和与癌症相关的疾病。本发明还包括包括这些化合物的药物组合物以及治疗与极化激酶活性相关的疾病状态的方法。
• AURORA KINASE MODULATORS AND METHOD OF USE
  申请人：Deak Holly

  公开号：US20100280008A1

  公开（公告）日：2010-11-04

  The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1-8、D'、L1、L2、R1、R6-8和n在此定义，并且合成中间体能够调节各种蛋白激酶受体酶，从而影响与这些激酶活动相关的各种疾病状态和条件。例如，这些化合物能够调节极化分裂激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物以及治疗与极化分裂激酶活性相关的疾病状态的方法。
• EP2137177B1
  申请人：——

  公开号：EP2137177B1

  公开（公告）日：2014-05-07
• US7776857B2
  申请人：——

  公开号：US7776857B2

  公开（公告）日：2010-08-17